Recent Events & Catalysts
Tarsus Pharmaceuticals, Inc. (TARS) — real, dated facts. Not a claim about what caused any single day's price move.
Committee Signals
Proprietary signals generated by the Innellis AI committee — score changes, rating shifts, and analyst disagreements.
No committee signals recorded yet.
News
Tarsus Pharmaceuticals Q2 EPS $(0.43) Misses $(0.20) Estimate, Sales $173.912M Beat $169.677M Estimate
Benzinga · 5d ago
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
SeekingAlpha · 5d ago
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
SeekingAlpha · 5d ago
Tarsus Pharmaceuticals To Acquire Alkeus Pharmaceuticals, A Closely Held Biotech Firm Developing Gildeuretinol, An Investigational Once-Daily Oral Therapy For Stargardt Disease; Terms Not Disclosed
Benzinga · 5d ago
Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98
Benzinga · 11d ago
SEC Filings (90 days)
Results of operations (earnings release), Financial statements and exhibits
Filed 2026-08-06 · 5d ago · Material
Entry into a material agreement, Unregistered sales of equity securities, Other events, Financial statements and exhibits
Filed 2026-08-06 · 5d ago
Entry into a material agreement, Unregistered sales of equity securities, Other events, Financial statements and exhibits
Filed 2026-08-06 · 5d ago
Departure/appointment of directors or officers
Filed 2026-07-13 · 29d ago
Entry into a material agreement, Unregistered sales of equity securities, Other events, Financial statements and exhibits
Filed 2026-07-08 · 34d ago
Earnings
No recent earnings data available.
Latest Analyst Action
No recent analyst actions available.